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1. Introduction 
Human erythrocytes contain a specific NADP(H)- 
binding protein, tentatively designated FX [ 1,2] , 
whose molecular properties have been previously 
described. [3] . A radioimmunoassay, based on double- 
antibody technique, was_ developed in order to quanti- 
tate this holoprotein in crude as well as in purified 
systems [4]. Preliminary application of the radio- 
immunoassay showed that the amount of FX cross 
reacting material (CRM) is significantly enhanced in 
hemolysates from individuals affected by the Medi- 
terranean type of glucose 6-phosphate dehydrogenase 
(G6PD) deficiency when compared with hemolysates 
from normal subjects. This finding appeared to be of 
interest because: 
(i) Little is known on the pathophysiology of the 
G6PD-deficient erythrocytes. 
(ii) The biological function of FX is still undetermined. 
Accordingly, the technique was improved by develop- 
ing a solid-phase radioimmunoassay whereby the 
content of FX CRM could be estimated throughout 
the life-span of the erythrocytes. The results obtained 
are consistent for distinctive patterns of decline of 
FX CRM during aging of normal and of G6PD 
Mediterranean erythrocytes, these patterns accounting 
for the different levels of the protein in whole cell 
populations from the two groups of subjects. 
2. Materials and methods 
2.1. Blood samples 
These were obtained from male subjects only. 
G6PD phenotypes were classified according to [5], 
as described elsewhere [4,6]. Blood samples were 
defibrinated with glass beads and erythrocytes were 
subjected to three washings with 5 vol. 0.15 M KCl, 
then submitted to enzyme assays or to fractionation 
according to age (see below). 
2.2. Assays of G6PD activity and determination of 
protein 
Hemolysates were prepared by diluting 1 vol. packed 
erythrocytes with 6 vol. cold Hz0 containing 10 /.LM 
NADP+. G6PD activity in normal hemolysates was 
estimated according to the Clock and McLean method 
[7] in the assay conditions recommended by [ 51. In 
the deficient subjects (screened by brilliant cresyl 
blue method [ 51 ), G6PD activity was measured in the 
presence of saturating amounts of G6PD and NADP+ 
only [8] . 
Protein was determined according to Lowry et al. 
[9] using standard solutions of ovalbumin. 
2.3. Separation of erythrocytes according to age 
Packed erythrocytes were centrifuged on dis- 
continuous gradients of Stractan II as reported by 
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Corash et al. [lo] . Four erythrocyte layers appeared 
following centrifugation, which were collected by 
suction with a Perpex LKB peristaltic pump. These 
were defined as Fractions I, II, III and IV, respectively, 
from the top to the bottom of each tube and corre- 
sponded to erythrocytes of increasing age, as indicated 
by the patterns of decline of G6PD activity [ 111 and 
of the reticulocyte percentage. 
2.4. Antisera and purified FX preparations 
FX was purified from pooled human erythrocytes 
as previously described [2]. The purity of the final 
preparations was tested by centrifugation on a Spinco 
Mod. E ultracentrifuge and by polyacrylamide gel 
electrophoresis in the presence of SDS [2]. 
Antiserum to homogeneous FX was raised in 
rabbits as previously reported [4] . The anti-FX serum 
was heat inactivated and adsorbed sequentially with 
human erythrocytes and with a purified IgC fraction 
from pooled human sera [4]. The specificity of the 
antiserum was checked by radial immunodiffusion 
against crude hemolysates. The immunoadsorbent was 
prepared by reacting 100 mg purified IgC fraction 
from the anti-FX serum with 20 g BrCN-activated 
agarose (1.50 mg BrCN/I g Sepharose 4 B). The 
reaction was allowed to proceed for 24 h at 4°C in 
16 ml 0.1 M NaHCOa, pH 9.0. Then the resin was 
reacted with 40 ml 1 M ethanolamine-HCl, pH 9.0, 
for 2 h at 4°C washed with Hz0 and treated with 
2 M Na acetate, pH 4.0, before being equilibrated with 
PBS. 
2.5. Solid-phase radioimmunoassay of FX 
Radioiodination of homogeneous FX was carried 
out using the lactoperoxidase catalyzed method of 
Marchalonis [ 121, as previously described [4]. The 
radioimmunoassay was based upon the capacity of 
crude hemolysates or of FX preparations of varying 
degrees of purity to inhibit the reaction between the 
above immunoadsorbent and ‘251-labeled FX. Different 
volumes (at least three) of each hemolysate tested 
were mixed in plastic tubes with a constant amount 
of immunoadsorbent which had been established in 
previous experiments to bind 50% of radioiodinated 
FX (1 pg) in the absence of unlabeled FX. Ovalbumin 
and concentrated PBS were added in order to nor- 
malize the assay mixtures for protein concentration 
(25 mg/ml) and PBS molarity (20 mM Na phosphate, 
224 
pH 7.0, containing 0.15 M NaCl), since both param- 
eters were found to affect the radioimmunoassay 
critically. After rotating the tubes for 150 min at 
4°C I Kg ‘251-labeled FX (in PBS containing 3% 
ovalbumin, w/v) was added and the mixtures were 
rotated for additional 150 min at 4°C. The tubes 
were centrifuged at 2500 rev./min and both the 
supernatants and the pellets (after one washing with 
I .O ml PBS) were counted for radioactivity. Blank 
assays were run in parallel, in which the usual immuno- 
adsorbent was replaced by a Sepharose-bound IgG 
fraction from anti-bovine serum albumin serum. The 
amount of FX CRM present in the sample tested was 
estimated by interpolation on a curve obtained by 
allowing known amounts of pure FX to compete 
with ‘251-labeled FX for the immunoadsorbent. 
3. Results 
3. I. Levels of immunoreactive FX in normal and 
G6PD Mediterranean erythrocytes 
Table 1 reports average values of FX CRM deter- 
mined in hemolysates from nineteen control subjects 
(carrying the G6PD B phenotype) and from twenty- 
seven individuals having the G6PD Mediterranean 
variant, respectively. As shown in the table, FX levels 
were significantly enhanced in G6PD Mediterranean 
erythrocytes as compared with normals. However, this 
increase was not generalized because five out of the 
twenty-seven G6PD-deficient subjects examined had a 
normal or slightly decreased erythrocyte content of 
FX CRM. No correlation was apparent, within either 
group of subjects, between actual levels of residual 
GGPD activity and levels of FX. 
Table 1 








45.46 f 10.57a 
77.51 f 32.48a 
aValues are means f SD 
The number of subjects is given in parentheses 
Significance between means, p<O.O005 
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3.2. Decay of immunoreactive FX during aging of 
erythrocytes 
The content of FX CRM was investigated in 
erythrocytes of different age together with values of 
G6PD activity which is a typical marker of erythro- 
cyte aging [ 11.13,14] . Figure 1 illustrates the results 
obtained in six normal individuals. Although a certain 
variability was observed among the subjects under 
study, there was a tendency to a progressive decline 
in the FX levels during the life-span of the control 
erythrocytes. 
The situation was entirely different in the group of 
subjects carrying the G6PD Mediterranean variant 
(fig.2). Thus, apart from the consistently enhanced 
rate of inactivation of G6PD during aging [ 111, the 
average content of FX in the young erythrocytes 
appears to be higher than in the corresponding fraction 
from the normal subjects. Moreover, no decay in FX 
levels from the young to the old erythrocyte fractions 
could be detected in any of the subjects investigated. 










Fig.1. Levels of G6PD activity and FX CRM in differently 
aged erythrocyte fractions from normal subjects (carrying the 
G6PD B phenotype). White columns, G6PD activity. Hatched 
columns, FX CRM. Fraction IV could not be assayed in sub- 
ject A.D.F. because of lack of material, while assay of FX 
CRM in Fraction I from subject G.F.G. was not performed. 
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Fig.2. Levels of G6PD activity and FX CRM in differently 
aged erythrocyte fractions from G6PDdeficient subjects 
carrying the Mediterranean variant. White columns, G6PD 
activity. Hatched columns, FX CRM. Fraction IV could 
not be assayed in subject P.D. because of lack of material. 
FX CRM in Fraction I from subjects A.R. and P.T. was not 
4. Discussion 
The enhanced content of immunoreactive FX in 
the G6PD Mediterranean erythrocytes cannot be 
accounted for by direct conversion of the G6PD 
variant to FX itself, since the two proteins seem to be 
coded by different structural genes [4]. However, the 
imbalance between levels of the two NADP(H)-binding 
proteins appears to be a characteristic feature in the 
Mediterranean type of G6PD deficiency. 
The data reported in this paper provide some infor- 
mation as to the mechanisms resulting in the above- 
mentioned steady-state levels of both FX and G6PD. 
Thus, FX shows a decline throughout the life-span of 
the normal erythrocyte, yet such decay is not as 
pronounced as for other proteins including fructose 
1,6-biphosphate aldolase [ 151 , pyruvate kinase [ 161, 
acetylcholinesterase [ 171 , adenylate cyclase [ 181 , 
protein kinase [ 181, purine nucleoside phosphorylase 
[ 191 and G6PD [ 11,131. In the G6PD Mediterranean 
erythrocytes the amount of FX CRM is higher within 
the young cells and remains constant during aging, 
225 
Volume 82, number 2 FEBS LETTERS October 1977 
both facts leading to the increased content of this 
protein in whole erythrocyte populations (table 1). 
The consistently accelerated breakdown of GBPD 
Mediterranean [6] , as compared with the normal B 
phenotype, can be easily explained on the assumption 
that the underlying structural mutation renders the 
protein more susceptible to removal by the still 
unknown cellular systems involved therein. Conversely, 
the concurrent resistance of FX to degradation can 
hardly be explained in terms of a modified protein 
structure, since: 
(i) No evidence is still available for an additional 
mutation affecting also the FX locus. 
(ii) Even if such mutation were involved, it would be 
expected to determine an enhanced degradation 
of the protein. 
Rather, failure to observe any decrease in the FX 
content during aging could reflect a ‘spare’ mechanism 
secondary to the accelerated removal of mutant 
G6PD, thus suggesting that common systems may be 
responsible for the decay of both NADP(H)-binding 
proteins. 
The finding of a small proportion of G6PD 
Mediterranean subjects showing normal rather than 
increased levels of immunoreactive FX remains so far 
unexplained. Further studies are required in order to 
verify whether such unusual feature is related to any 
genetic polymorphism within the Mediterranean type 
of G6PD deficiency. 
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